Supplementation with 2'-fucosyllactose, a prebiotic human milk oligosaccharide (HMO), in a magnesium-containing medical food reduces chemotherapy-induced mucositis in Wistar rats.

Authors

Sourabh Kharait, Matthew Wilcox, Kyle Stockdale-Stanforth, Vishnu Thakare

Published in

Frontiers in nutrition. Volume 13. Pages 1859479. Epub Jun 25, 2026.

Abstract

Mucositis is a common debilitating complication of chemotherapy in cancer patients that limits enteral nutrition, causes diarrhea, dehydration and electrolyte wasting. 2'-fucosyllactose (2'-FL), a non-digestible oligosaccharide initially isolated from human milk, is critical in the development of gastrointestinal function and microbiome maturation in the newborn. Here, we demonstrate, that supplementation of 2'-FL in a medical food with magnesium (Humolyte®), protects Wistar rats from gastrointestinal mucosal injury from chemotherapeutic drugs doxorubicin, irinotecan, 5-flurouracil, and cisplatin. Supplementation with Humolyte® reduced weight loss and the severity of diarrhea from chemotherapy. Histopathology of ileal and colonic tissue showed preservation of overall mucosal anatomy including goblet cells and a markedly lesser inflammation. Humolyte® reduced hypertrophy and edema of oral mucosa caused by chemotherapy. In vitro, Humolyte® improved goblet cell survival and mucin secretion while reducing monolayer permeability. Thus, Humolyte® can be a useful adjunctive therapy for patients with cancer suffering from chemotherapy-induced mucositis.

PMID:
42428609
Bibliographic data and abstract were imported from PubMed on 10 Jul 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.